United States FDA drug approvals are persistent and polycyclic: Insights into economic cycles, innovation dynamics, and national policy
It is challenging to elucidate the effects of changes in external influences (such as economic or policy) on the rate of US drug approvals. Here, a novel approach, termed the Chronological Hurst Exponent (CHE), is proposed, which hypothesizes that changes in the long-range memory latent within the dynamics of time series data may be temporally associated with changes in such influences. Using the monthly number the FDA Center for Drug Evaluation and Research (CDER) approvals from 1939 to 2019 as the data source, it is demonstrated that the CHE has a distinct S-shaped structure demarcated by an 8-year (1939-1947) Stagnation Period, a 27-year (1947-1974) Emergent (time-varying Period, and a 45-year (1974-2019) Saturation Period. Further, dominant periodicities (resolved via wavelet analyses) are identified during the most recent 45-year CHE Saturation Period at 17, 8 and 4 years; thus, US drug approvals have been following a Juglar-Kuznet mid-term cycle with Kitchin-like bursts. As discussed, this work suggests that (1) changes in extrinsic factors (e.g., of economic and/or policy origin ) during the Emergent Period may have led to persistent growth in US drug approvals enjoyed since 1974, (2) the CHE may be a valued method to explore influences on time series data, and (3) innovation-related economic cycles exist (as viewed via the proxy metric of US drug approvals).
Code (0)
등록된 구현이 없습니다.
Tasks
Time SeriesTime Series AnalysisSimilar Papers 제목 키워드 기반
A comparison of heroin epidemic models
The use of illicit drugs has been on the rise in United States. It is very detrimental on society, as fatal overdose is the fourth leading cause of death in the United States, which is about the same as motor vehicle cra…
Singular Secular Kuznets-like Period Realized Amid Industrial Transformation in US FDA Medical Devices: A Perspective on Innovation from 1976 to 2020
Introduction: Since inception, the United States (US) Food and Drug Administration (FDA) has kept a robust record of regulated medical devices (MDs). Based on these data, can we gain insight into the innovation dynamics …
MarketingMultiscale Topology in Interactomic Network: From Transcriptome to Antiaddiction Drug Repurposing
The escalating drug addiction crisis in the United States underscores the urgent need for innovative therapeutic strategies. This study embarked on an innovative and rigorous strategy to unearth potential drug repurposin…
Drug DiscoveryTopological Data AnalysisThe impact of external innovation on new drug approvals: A retrospective analysis
Pharmaceutical companies are relying more often on external sources of innovation to boost their discovery research productivity. However, more in-depth knowledge about how external innovation may translate to successful…
Visibility graph analysis of economy policy uncertainty indices
Uncertainty plays an important role in the global economy. In this paper, the economic policy uncertainty (EPU) indices of the United States and China are selected as the proxy variable corresponding to the uncertainty o…
Clustering